SCHEMBL535143

SCHEMBL535143

COc1ccc(-c2cc(=O)c3cc(C)ccc3o2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 3/20 1.00
KCNH2 Q12809 3/20 1.00
MAPT P10636 5/20 0.81
KDM4E B2RXH2 4/20 0.81
ALDH1A1 P00352 4/20 0.81
TP53 P04637 4/20 0.81
CYP3A4 P08684 4/20 0.81
HPGD P15428 4/20 0.81
NPC1 O15118 3/20 0.81
RAB9A P51151 3/20 0.81
HSD17B10 Q99714 3/20 0.81
NFKB1 P19838 2/20 0.81
NFKB2 Q00653 2/20 0.81
RELA Q04206 2/20 0.81
LMNA P02545 2/20 0.81
THRB P10828 2/20 0.81
SMN1; SMN2 Q16637 2/20 0.81
RXFP1 Q9HBX9 1/20 0.81
CSNK2A2 P19784 3/20 0.73
CSNK2B P67870 3/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
6,4'-Dimethoxyflavone SCHEMBL29478471 0.90 MAPT (1.00) KCNA5KCNH2MAPTKDM4EALDH1A1
6,4'-Dimethoxyflavone SCHEMBL4281291 0.90 MAPT (1.00) KCNA5KCNH2MAPTKDM4EALDH1A1
SCHEMBL28154767 0.89 MAOB (0.86) KCNA5KCNH2MAPTKDM4EALDH1A1
SCHEMBL10024074 0.88 CSNK2A2 (0.82) KCNA5KCNH2MAPTKDM4EALDH1A1
SCHEMBL31238310 0.86 MAPT (0.91) KCNA5KCNH2MAPTKDM4EALDH1A1
SCHEMBL4990151 0.84 GABRP (1.00) KCNA5KCNH2MAPTKDM4EALDH1A1
SCHEMBL13169617 0.84 MAOB (0.80) KCNA5KCNH2MAPTKDM4EALDH1A1
SCHEMBL490928 0.84 MAPT (1.00) KCNA5KCNH2MAPTKDM4EALDH1A1
SCHEMBL31675989 0.84 MAPT (1.00) KCNA5KCNH2MAPTKDM4EALDH1A1
SCHEMBL4983190 0.84 APP (1.00) KCNA5KCNH2MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed
EP-2863875-B1 MOUTH RINSE EMULSIONS PROCTER & GAMBLE (US) 2018-08-22 EP disclosed
EP-2730431-B1 Rubber composition and tire with rubber containing flavone GOODYEAR TIRE & RUBBER (US) 2017-06-28 EP disclosed
EP-2863875-A2 MOUTH RINSE EMULSIONS The Procter & Gamble Company (US) 2015-04-29 EP disclosed
EP-2415473-B1 ORAL CARE COMPOSITIONS CONTAINING COMBINATIONS OF ANTI-BACTERIAL AND HOST-RESPONSE MODULATING AGENTS PROCTER & GAMBLE (US) 2014-09-17 EP disclosed
US-20140135433-A1 TIRE WITH RUBBER CONTAINING FLAVONE THE GOODYEAR TIRE & RUBBER COMPANY (US) 2014-05-15 US disclosed
EP-2730431-A1 Rubber composition and tire with rubber containing flavone The Goodyear Tire & Rubber Company (US) 2014-05-14 EP disclosed
WO-2013192382-A2 MOUTH RINSE EMULSIONS THE PROCTER & GAMBLE COMPANY (US) 2013-12-27 WO disclosed
US-20130344120-A1 Mouth Rinse Emulsions THE PROCTER & GAMBLE COMPANY 2013-12-26 US disclosed
EP-1391327-A1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2004-02-25 EP disclosed
EP-1379524-A2 CHROMANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS Pharmacia Italia S.p.A. (IT) 2004-01-14 EP disclosed
WO-2003057210-A1 COMPOSITIONS AND METHODS FOR INCREASING CELL PROLIFERATION COMPRISING A FLAVONOID KIMBERLY-CLARK WORLDWIDE, INC. (US) 2003-07-17 WO disclosed
US-20030125264-A1 Methods For Treating Wounds KIMBERLY-CLARK WORLDWIDE, INC. 2003-07-03 US disclosed
US-6555523-B1 Such as 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment HIV, picornavirus, and/or respiratory virus CASCADE ESTATES LTD. (MU) 2003-04-29 US disclosed
WO-2002070515-A2 CHROMANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA ITALIA SPA (IT) 2002-09-12 WO disclosed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP disclosed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125264-A1 Methods For Treating Wounds FGF2, MMP1, FIBP KCNA5 4498/4885KCNH2 2555/4885MAPT 4313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.